Is It Time To Buy Regeneron Pharmaceuticals Stock?
4/6 05:33
Regeneron Pharmaceuticals (NASDAQ:REGN) shares experienced a significant 19% drop on Friday, May 30, following the unexpected failure of itepekimab, its chronic obstructive pulmonary disease (COPD) treatment partnered with Sanofi, in a late stage clinical trial. One of the two tr...